View Financial HealthMedicure 配当と自社株買い配当金 基準チェック /06Medicure配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026お知らせ • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canadaお知らせ • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025お知らせ • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025お知らせ • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025お知らせ • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canadaお知らせ • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.お知らせ • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024お知らせ • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.お知らせ • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.お知らせ • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024お知らせ • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.お知らせ • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023お知らせ • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.決済の安定と成長配当データの取得安定した配当: MCUJ.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MCUJ.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Medicure 配当利回り対市場MCUJ.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MCUJ.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (MCUJ.F) (最長3年)n/a注目すべき配当: MCUJ.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MCUJ.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MCUJ.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MCUJ.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 13:47終値2026/05/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medicure Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Andre UddinResearch Capital CorporationRobert GibsonVentum Financial Corp
お知らせ • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026
お知らせ • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada
お知らせ • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025
お知らせ • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025
お知らせ • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025
お知らせ • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada
お知らせ • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.
お知らせ • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024
お知らせ • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.
お知らせ • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.
お知らせ • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024
お知らせ • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.
お知らせ • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023
お知らせ • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.